title: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy].
abstract: RAS mutation is an established predictive biomarker of resistance to anti-epidermal growth factor receptor(EGFR)therapy in metastatic colorectal cancer. In addition, previous studies identified mutations in ERBB2, FGFR1, PDGFRA, BRAF, MAP2K1, PTEN, and PIK3CA as potential mechanisms of resistance to anti-EGFR therapy. Testing for these mutations might be necessary to determine eligibility for anti-EGFR therapy in patients with metastatic colorectal cancer. CancerPlex®is a nextgeneration sequencer for 413 cancer genes. An analysis panel includes genes that may be associated with resistance to anti- EGFR therapy. A 65-year-old man with unresectable rectal cancer, multiple lung metastases, and a bulky liver metastasis was evaluated for expression of genes associated with resistance to anti-EGFR. The analysis found that all genes indicating resistance were wild-type genes. Cetuximab monotherapy was administered after rectal resection, with dramatic shrinkage of the metastatic tumors. A more accurate selection of patients according to tumor genetic status using CancerPlex®might improve the risk-benefit profile of anti-EGFR therapy.
authors.affiliation: Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences.
authors.forename: Ryoma
authors.initials: R
authors.lastname: Yagi
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Shimada
authors.forename: Kohei
authors.initials: K
authors.lastname: Miura
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Tajima
authors.forename: Takuma
authors.initials: T
authors.lastname: Okamura
authors.forename: Masato
authors.initials: M
authors.lastname: Nakano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ichikawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nagahashi
authors.forename: Jun
authors.initials: J
authors.lastname: Sakata
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kameyama
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Wakai
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nogami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Maruyama
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Takii
mesh_terms: D000368:Aged; D000068818:Cetuximab / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009154:Mutation; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab